clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-5-6-415-421clinmed-858Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСамостоятельное тестирование на вирус папилломы человека как скрининговый метод выявления групп рискаSelf-testing for human papillomavirus as a screening method for identifying risk groupshttps://orcid.org/0000-0001-6104-9842ГромоваТ. А.GromovaT. A.

Громова Татьяна Александровна — канд. мед. наук., ассистент кафедры акушерства и гинекологии ИКМ им. Н.В. Склифосовского

Москва

Tatyana A. Gromova — Candidate of Medical Sciences, Assistant of the Department of Obstetrics and Gynecology of Sklifosovsky Institute for Emergency Medicine

Moscow

tgromova928@yandex.ruhttps://orcid.org/0000-0002-4591-838XЛеваковС. А.LevakovS. A.

Леваков Сергей Александрович — д-р мед. наук, профессор, заведующий кафедрой акушерства и гинекологии ИКМ им. Н.В. Склифосовского

Москва

Sergey A. Levakov — Doctor of Medical Sciences, Professor, Head of the Department of Obstetrics and Gynecology of Sklifosovsky Institute for Emergency Medicine

Moscow

https://orcid.org/0009-0007-7494-5807МушкюроваД. Р.MushkyurovaD. R.

Мушкюрова Диана Рамазановна — аспирант кафедры акушерства и гинекологии ИКМ им. Н.В. Склифосовского

Москва

Diana R. Mushkyurova — postgraduate student of the Department of Obstetrics and Gynecology of Sklifosovsky Institute for Emergency Medicine

Moscow

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)Russian Federation2024071120241025-6415421Copyright © Громова Т.А., Леваков С.А., Мушкюрова Д.Р., 20242024Громова Т.А., Леваков С.А., Мушкюрова Д.Р.Gromova T.A., Levakov S.A., Mushkyurova D.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/858

В связи с высокой распространенностью рака шейки матки необходимо проведение мероприятий, направленных на уменьшение его частоты за счет вакцинации, проведения скрининга, выявления и лечения предраковых состояний. В статье представлен системный анализ научных данных использования тестирования для самостоятельного отбора проб на вирус папилломы человека как инструмента повышения эффективности скрининга и выявления предраковых заболеваний шейки матки. Показано, что использование подобных тестов, которые основаны на полимеразной цепной реакции, имеют схожую клиническую точность по сравнению с забором материала врачом. Таким образом, данный вариант является перспективным способом расширения охвата скринингом на рак шейки матки за счет тестирования пациенток, не проходивших обследование. Наличие предполагаемой экономической эффективности также предопределяет актуальность и перспективность данных тестов. Однако необходимо проведение дальнейших исследований, направленных на оценку внедрения данной стратегии в рутинную практику.

Due to the high prevalence of cervical cancer, it is necessary to take measures aimed at reducing its frequency through vaccination, screening, detection and treatment of precancerous conditions. The article presents a systematic analysis of scientific data on the use of testing for self-sampling for human papillomavirus as a tool to improve the effectiveness of screening and detection of precancerous diseases of the cervix. It has been shown that the use of such tests, which are based on polymerase chain reaction (PCR), have similar clinical accuracy compared to sampling by a doctor, and thus this option is promising for expanding the coverage of cervical cancer screening. The presence of expected economic efficiency also determines the relevance and prospects for these tests, but further research is needed to assess their implementation in routine practice.

цервикальная интраэпителиальная неоплазиярак шейки маткискринингсамостоятельное тестирование на вирус папилломы человекаcervical intraepithelial neoplasiacervical cancerscreeningself-testing for human papillomavirusReferencesSung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. DOI: 10.3322/caac.21660Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. DOI: 10.3322/caac.21660Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI: 10.3322/caac.21492Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI: 10.3322/caac.21492Female Genital Tumours. WHO Classification of Tumors. 5th ed. Volume 4 WHO Press; Geneva, Switzerland. 2020.Female Genital Tumours. WHO Classification of Tumors. 5th ed. Volume 4 WHO Press; Geneva, Switzerland. 2020.Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int. J. Cancer. 2021;149:778–789. DOI: 10.1002/ijc.33588Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int. J. Cancer. 2021;149:778–789. DOI: 10.1002/ijc.33588Brisson M., Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019;20:319–21. DOI: 10.1016/S1470-2045(19)30072-5Brisson M., Drolet M. Global elimination of cervical cancer as a public health problem. Lancet Oncol. 2019;20:319–21. DOI: 10.1016/S1470-2045(19)30072-5Canfell K., Kim J.J., Brisson M., Keane A., Simms K.T., Caruana M. et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020; 395(10224):591–603. DOI: 10.1016/S0140-6736(20)30157-4Canfell K., Kim J.J., Brisson M., Keane A., Simms K.T., Caruana M. et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020; 395(10224):591–603. DOI: 10.1016/S0140-6736(20)30157-4Brisson M., Kim J.J., Canfell K., Drolet M., Gingras G., Burger E.A. et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575–590. DOI: 10.1016/S0140-6736(20)30068-4Brisson M., Kim J.J., Canfell K., Drolet M., Gingras G., Burger E.A. et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575–590. DOI: 10.1016/S0140-6736(20)30068-4WHO Goal 3: Ensure healthy lives and promote well-being for all at all ages. Target 3.4: by 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being. Indicator 3.4.1: mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease. 2017. [Electronic resource]. URL: https://unstats.un.org/sdgs/metadata/files/Metadata-03-04-01.pdfWHO Goal 3: Ensure healthy lives and promote well-being for all at all ages. Target 3.4: by 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being. Indicator 3.4.1: mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease. 2017. [Electronic resource]. URL: https://unstats.un.org/sdgs/metadata/files/Metadata-03-04-01.pdfWorld Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. WHO. 2021. [Electronic resource]. URL: https://www.who.int/publications/i/item/9789240014107World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. WHO. 2021. [Electronic resource]. URL: https://www.who.int/publications/i/item/9789240014107Zhang Q., Xie W., Wang F., Li R.H., Cui L., Wang H., Fu X., Song J. Epidemiological Investigation and Risk Factors for Cervical Lesions: Cervical Cancer Screening Among Women in Rural Areas of Henan Province China. Med. Sci. Monit. 2016;22:1858–1865. DOI: 10.12659/MSM.894663Zhang Q., Xie W., Wang F., Li R.H., Cui L., Wang H., Fu X., Song J. Epidemiological Investigation and Risk Factors for Cervical Lesions: Cervical Cancer Screening Among Women in Rural Areas of Henan Province China. Med. Sci. Monit. 2016;22:1858–1865. DOI: 10.12659/MSM.894663American Cancer Society. The American Cancer Society Guidelines for the Prevention and Early Detection of Cervical Cancer. 2022. [Electronic resource]. URL: https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/cervical-cancer-screening-guidelines.htmlAmerican Cancer Society. The American Cancer Society Guidelines for the Prevention and Early Detection of Cervical Cancer. 2022. [Electronic resource]. URL: https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/cervical-cancer-screening-guidelines.htmlYeo-Teh N.S.L., Ito Y., Jha S. High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int. J. Mol. Sci. 2018;19:1706. DOI: 10.3390/ijms19061706Yeo-Teh N.S.L., Ito Y., Jha S. High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. Int. J. Mol. Sci. 2018;19:1706. DOI: 10.3390/ijms19061706Volkova L.V., Pashov A.I., Omelchuk N.N. Cervical carcinoma: oncobiology and biomarkers. Int. J. Mol. Sci. 2021; 22(22):12571. (In Russian)]. DOI: 10.3390/ijms222212571Volkova L.V., Pashov A.I., Omelchuk N.N. Cervical carcinoma: oncobiology and biomarkers. Int. J. Mol. Sci. 2021; 22(22):12571. (In Russian)]. DOI: 10.3390/ijms222212571IARC Working Group. Human Papillomaviruses: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer. Accessed May 2, 2021. [Electronic resource]. URL: https://monographs.iarc.who.int/wp‐content/uploads/2018/06/mono90.pdfIARC Working Group. Human Papillomaviruses: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer. Accessed May 2, 2021. [Electronic resource]. URL: https://monographs.iarc.who.int/wp‐content/uploads/2018/06/mono90.pdfКлинические рекомендации. Цервикальная интраэпителиальная неоплазия, эрозия и эктропион шейки матки. 2022; Министерство здравоохранения Российской Федерации.Klinicheskie rekomendacii. Cervikalnaya intraepitelialnaya neoplaziya, eroziya i ektropion shejki matki. 2022; Ministerstvo zdravoohraneniya Rossijskoj Federacii. (In Russian). [Electronic resource]. URL: https://cr.minzdrav.gov.ru/schema/597_1Piña-Sánchez P. Human Papillomavirus: Challenges and Opportunities for the Control of Cervical Cancer. Arch. Med. Res. 2022;53(8):753–769. DOI: 10.1016/j.arcmed.2022.11.009Piña-Sánchez P. Human Papillomavirus: Challenges and Opportunities for the Control of Cervical Cancer. Arch. Med. Res. 2022;53(8):753–769. DOI: 10.1016/j.arcmed.2022.11.009Markowitz L.E., Schiller J.T. Human Papillomavirus Vaccines. J. Infect. Dis. 2021; 224(12):367–S378. DOI: 10.1093/infdis/jiaa621Markowitz L.E., Schiller J.T. Human Papillomavirus Vaccines. J. Infect. Dis. 2021; 224(12):367–S378. DOI: 10.1093/infdis/jiaa621de Martel C., Plummer M., Vignat J., Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017;141(4):664–670. DOI: 10.1002/ijc.30716de Martel C., Plummer M., Vignat J., Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int. J. Cancer. 2017;141(4):664–670. DOI: 10.1002/ijc.30716Beachler D.C., Kreimer A.R., Schiffman M., Herrero R., Wacholder S., Rodriguez A.C. et al. Costa Rica HPV Vaccine Trial (CVT) Group. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J. Natl. Cancer Inst. 2015;108(1):djv302. DOI: 10.1093/jnci/djv302Beachler D.C., Kreimer A.R., Schiffman M., Herrero R., Wacholder S., Rodriguez A.C. et al. Costa Rica HPV Vaccine Trial (CVT) Group. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J. Natl. Cancer Inst. 2015;108(1):djv302. DOI: 10.1093/jnci/djv302Bruni L., Albero G., Serrano B., Mena M., Collado J.J., Gómez D. et al. ICO/IARC Information centre on HPV and cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. 2023. [Electronic resource]. URL: https://hpvcentre.net/statistics/reports/XWX.pdfBruni L., Albero G., Serrano B., Mena M., Collado J.J., Gómez D. et al. ICO/IARC Information centre on HPV and cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. 2023. [Electronic resource]. URL: https://hpvcentre.net/statistics/reports/XWX.pdfAlarcón-Romero L.D.C., Organista-Nava J., Gómez-Gómez Y., Ortiz-Ortiz J., Hernández-Sotelo D., Del Moral-Hernández O. et al. Prevalence and distribution of human papillomavirus genotypes (1997-2019) and their association with cervical cancer and precursor lesions in women from Southern Mexico. Cancer Control. 2022;29:10732748221103331. DOI: 10.1177/10732748221103331Alarcón-Romero L.D.C., Organista-Nava J., Gómez-Gómez Y., Ortiz-Ortiz J., Hernández-Sotelo D., Del Moral-Hernández O. et al. Prevalence and distribution of human papillomavirus genotypes (1997-2019) and their association with cervical cancer and precursor lesions in women from Southern Mexico. Cancer Control. 2022;29:10732748221103331. DOI: 10.1177/10732748221103331Shen-Gunther J., Xia Q., Cai H., Wang Y. HPV DeepSeq: An ultra-fast method of NGS Data analysis and visualization using automated workflows and a customized papillomavirus database in CLC genomics workbench. Pathogens. 2021;10(8):1026. DOI: 10.3390/pathogens10081026Shen-Gunther J., Xia Q., Cai H., Wang Y. HPV DeepSeq: An ultra-fast method of NGS Data analysis and visualization using automated workflows and a customized papillomavirus database in CLC genomics workbench. Pathogens. 2021;10(8):1026. DOI: 10.3390/pathogens10081026Vargas-Robles D., Magris M., Morales N., de Koning M.N.C., Rodríguez I., Nieves T. et al. . High rate of infection by only oncogenic human papillomavirus in amerindians. mSphere. 2018;3(3):e00176– 18. DOI: 10.1128/mSphere.00176-18Vargas-Robles D., Magris M., Morales N., de Koning M.N.C., Rodríguez I., Nieves T. et al. . High rate of infection by only oncogenic human papillomavirus in amerindians. mSphere. 2018;3(3):e00176– 18. DOI: 10.1128/mSphere.00176-18Basukala O., Banks L. The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis. Viruses. 2021;13(10):1892. DOI: 10.3390/v13101892Basukala O., Banks L. The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis. Viruses. 2021;13(10):1892. DOI: 10.3390/v13101892Liu M., Han Z., Zhi Y., Ruan Y., Cao G., Wang G. et al. Long-read sequencing reveals oncogenic mechanism of HPV-human fusion transcripts in cervical cancer. Transl. Res. 2023;253:80–94. DOI: 10.1016/j.trsl.2022.09.004Liu M., Han Z., Zhi Y., Ruan Y., Cao G., Wang G. et al. Long-read sequencing reveals oncogenic mechanism of HPV-human fusion transcripts in cervical cancer. Transl. Res. 2023;253:80–94. DOI: 10.1016/j.trsl.2022.09.004Zhang R., Shen C., Zhao L., Wang J., McCrae M., Chen X., Lu F. Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis. Int. J. Cancer. 2016;138(5):1163–74. DOI: 10.1002/ijc.29872Zhang R., Shen C., Zhao L., Wang J., McCrae M., Chen X., Lu F. Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis. Int. J. Cancer. 2016;138(5):1163–74. DOI: 10.1002/ijc.29872Xu B., Chotewutmontri S., Wolf S., Klos U., Schmitz M., Dürst M., Schwarz E. Multiplex identification of human papillomavirus 16 DNA integration sites in cervical carcinomas. PLoS One. 2013;8(6):e66693. DOI: 10.1371/journal.pone.006669Xu B., Chotewutmontri S., Wolf S., Klos U., Schmitz M., Dürst M., Schwarz E. Multiplex identification of human papillomavirus 16 DNA integration sites in cervical carcinomas. PLoS One. 2013;8(6):e66693. DOI: 10.1371/journal.pone.006669de Miguel F.J., Sharma R.D., Pajares M.J., Montuenga L.M., Rubio A., Pio R. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res. 2014;74(4):1105–15. DOI: 10.1158/0008-5472.CAN-13-1481de Miguel F.J., Sharma R.D., Pajares M.J., Montuenga L.M., Rubio A., Pio R. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res. 2014;74(4):1105–15. DOI: 10.1158/0008-5472.CAN-13-1481Sudenga S.L., Shrestha S. Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int. J. Infect Dis. 2013;17(4):e216–20. DOI: 10.1016/j.ijid.2012.12.027Sudenga S.L., Shrestha S. Key considerations and current perspectives of epidemiological studies on human papillomavirus persistence, the intermediate phenotype to cervical cancer. Int. J. Infect Dis. 2013;17(4):e216–20. DOI: 10.1016/j.ijid.2012.12.027Vats A., Trejo-Cerro O., Thomas M., Banks L. Human papillomavirus E6 and E7: What remains? Tumour Virus Res. 2021;11:200213. DOI: 10.1016/j.tvr.2021.200213Vats A., Trejo-Cerro O., Thomas M., Banks L. Human papillomavirus E6 and E7: What remains? Tumour Virus Res. 2021;11:200213. DOI: 10.1016/j.tvr.2021.200213Lei J., Ploner A., Lagheden C., Eklund C., Nordqvist Kleppe S., Andrae B., Elfström K.M., Dillner J., Sparén P., Sundström K. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med. 2018;15:e1002666. DOI: 10.1371/journal.pmed.1002666Lei J., Ploner A., Lagheden C., Eklund C., Nordqvist Kleppe S., Andrae B., Elfström K.M., Dillner J., Sparén P., Sundström K. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLoS Med. 2018;15:e1002666. DOI: 10.1371/journal.pmed.1002666Balasubramaniam S.D., Balakrishnan V., Oon C.E., Kaur G. Key molecular events in cervical cancer development. Medicina (Kaunas). 2019;55(7):384. DOI: 10.3390/medicina55070384Balasubramaniam S.D., Balakrishnan V., Oon C.E., Kaur G. Key molecular events in cervical cancer development. Medicina (Kaunas). 2019;55(7):384. DOI: 10.3390/medicina55070384Rahangdale L., Mungo C., O’Connor S., Chibwesha C.J., Brewer N.T. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379:e070115. DOI: 10.1136/bmj-2022-070115Rahangdale L., Mungo C., O’Connor S., Chibwesha C.J., Brewer N.T. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379:e070115. DOI: 10.1136/bmj-2022-070115Demarco M., Hyun N., Carter-Pokras O., Raine-Bennett T.R., Cheung L., Chen X. et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293. DOI: 10.1016/j.eclinm.2020Demarco M., Hyun N., Carter-Pokras O., Raine-Bennett T.R., Cheung L., Chen X. et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293. DOI: 10.1016/j.eclinm.2020Basu P., Malvi S.G., Joshi S., Bhatla N., Muwonge R., Lucas E.et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22(11):1518–1529. DOI: 10.1016/S1470-2045(21)00453-8Basu P., Malvi S.G., Joshi S., Bhatla N., Muwonge R., Lucas E.et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol. 2021;22(11):1518–1529. DOI: 10.1016/S1470-2045(21)00453-8FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old FDA. 2018. [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-oldFDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old FDA. 2018. [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-oldAmerican College of Obstetricians and Gynecologist. Updated Cervical Cancer Screening Guidelines. 2022. [Electronic resource]. URL: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelinesAmerican College of Obstetricians and Gynecologist. Updated Cervical Cancer Screening Guidelines. 2022. [Electronic resource]. URL: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelinesUnited Kingdom National Screening Committee Guidance. Cervical Screening: Programme Overview. 2022. [Electronic resource]. URL: https://www.gov.uk/guidance/cervical-screening-programme-overviewUnited Kingdom National Screening Committee Guidance. Cervical Screening: Programme Overview. 2022. [Electronic resource]. URL: https://www.gov.uk/guidance/cervical-screening-programme-overviewNational Cancer Institute Cervical Cancer Screening (PDQ®) - Health Professional Version. 2022. [Electronic resource]. URL: https://www.cancer.gov/types/cervical/hp/cervical-screening-pdqNational Cancer Institute Cervical Cancer Screening (PDQ®) - Health Professional Version. 2022. [Electronic resource]. URL: https://www.cancer.gov/types/cervical/hp/cervical-screening-pdqHong Kong Centre for Health Protection & Cancer Expert Working Group on Cancer Prevention and Screening Recommendations on Prevention and Screening for Cervical Cancer for Health Professionals. 2022. [Electronic resource]. URL: https://www.chp.gov.hk/en/recommendations/34/index.htmlHong Kong Centre for Health Protection & Cancer Expert Working Group on Cancer Prevention and Screening Recommendations on Prevention and Screening for Cervical Cancer for Health Professionals. 2022. [Electronic resource]. URL: https://www.chp.gov.hk/en/recommendations/34/index.htmlUnited States Preventive Services Task Force Screening for Cervical Cancer US Preventive Services Task Force Recommendation Statement. 2022. [Electronic resource]. URL: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screeningUnited States Preventive Services Task Force Screening for Cervical Cancer US Preventive Services Task Force Recommendation Statement. 2022. [Electronic resource]. URL: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screeningSawaya G.F., Kulasingam S., Denberg T.D., Qaseem A. Clinical guidelines committee of american college of physicians cervical cancer screening in average-risk women: best practice advice from the clinical guidelines committee of the american college of physicians. Ann. Intern. Med. 2015;162:851–859. DOI: 10.7326/M14-2426Sawaya G.F., Kulasingam S., Denberg T.D., Qaseem A. Clinical guidelines committee of american college of physicians cervical cancer screening in average-risk women: best practice advice from the clinical guidelines committee of the american college of physicians. Ann. Intern. Med. 2015;162:851–859. DOI: 10.7326/M14-2426Cancer council australia national cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. 2022. [Electronic resource]. URL: https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/summary-of-recommendationsCancer council australia national cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. 2022. [Electronic resource]. URL: https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening/summary-of-recommendationsThe royal australian college of general practitioners early detection of cancers. Cervical cancer. 2022. [Electronic resource]. URL: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgpguidelines/view-all-racgp-guidelines/guidelines-for-preventive-activities-in-general-pr/early-detection-of-cancers/cervical-cancerThe royal australian college of general practitioners early detection of cancers. Cervical cancer. 2022. [Electronic resource]. URL: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgpguidelines/view-all-racgp-guidelines/guidelines-for-preventive-activities-in-general-pr/early-detection-of-cancers/cervical-cancerCanadian task force on preventive health care recommendations on screening for cervical cancer. 2022. [Electronic resource]. URL: https://www.cmaj.ca/content/185/1/35.fullCanadian task force on preventive health care recommendations on screening for cervical cancer. 2022. [Electronic resource]. URL: https://www.cmaj.ca/content/185/1/35.fullThe royal australian college of general practitioners early detection of cancers. Cervical cancer. 2022. (accessed on 8 August 2022). [Electronic resource]. URL: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgpguidelines/guidelines-for-preventive-activities-in-general-pr/early-detection-of-cancers/cervical-cancerThe royal australian college of general practitioners early detection of cancers. Cervical cancer. 2022. (accessed on 8 August 2022). [Electronic resource]. URL: https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgpguidelines/guidelines-for-preventive-activities-in-general-pr/early-detection-of-cancers/cervical-cancerPolman N.J., Snijders P.J.F., Kenter G.G., Berkhof J., Meijer C.J.L.M. HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme. Prev. Med. 2019;119:108–117. DOI: 10.1016/j.ypmed.2018.12.021Polman N.J., Snijders P.J.F., Kenter G.G., Berkhof J., Meijer C.J.L.M. HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme. Prev. Med. 2019;119:108–117. DOI: 10.1016/j.ypmed.2018.12.021Zhang Q., Xie W., Wang F., Li R.H., Cui L., Wang H., Fu X., Song J. Epidemiological Investigation and Risk Factors for Cervical Lesions: Cervical Cancer Screening Among Women in Rural Areas of Henan Province China. Med. Sci. Monit. 2016;22:1858–65. DOI: 10.12659/msm.894663Zhang Q., Xie W., Wang F., Li R.H., Cui L., Wang H., Fu X., Song J. Epidemiological Investigation and Risk Factors for Cervical Lesions: Cervical Cancer Screening Among Women in Rural Areas of Henan Province China. Med. Sci. Monit. 2016;22:1858–65. DOI: 10.12659/msm.894663Sravani A.B., Ghate V,. Lewis S. Human papillomavirus infection, cervical cancer and the less explored role of trace elements. Biol. Trace Elem. Res. 2023; 201(3):1026–1050. DOI: 10.1007/s12011-022-03226-2Sravani A.B., Ghate V,. Lewis S. Human papillomavirus infection, cervical cancer and the less explored role of trace elements. Biol. Trace Elem. Res. 2023; 201(3):1026–1050. DOI: 10.1007/s12011-022-03226-2US Food and drug administration (FDA) executive summary: new approaches in the evaluation for high-risk human papillomavirus nucleic acid detection devices. 2020. [Electronic resource]. URL: https://www.fda.gov/media/122799/downloadUS Food and drug administration (FDA) executive summary: new approaches in the evaluation for high-risk human papillomavirus nucleic acid detection devices. 2020. [Electronic resource]. URL: https://www.fda.gov/media/122799/downloadUS Preventive Services Task Force; Curry S.J., Krist A.H., Owens D.K., Barry M.J., Caughey A.B., Davidson K.W. et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320(7):674–686. DOI: 10.1001/jama.2018.10897US Preventive Services Task Force; Curry S.J., Krist A.H., Owens D.K., Barry M.J., Caughey A.B., Davidson K.W. et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320(7):674–686. DOI: 10.1001/jama.2018.10897Salazar K.L., Duhon D.J., Olsen R., Thrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J. Am. Soc. Cytopathol. 2019; 8: 284–292. DOI: 10.1016/j.jasc.2019.06.001Salazar K.L., Duhon D.J., Olsen R., Thrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J. Am. Soc. Cytopathol. 2019; 8: 284–292. DOI: 10.1016/j.jasc.2019.06.001Bhatla N., Singhal S. Primary HPV screening for cervical cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2020;65:98–108. DOI: 10.1016/j.bpobgyn.2020.02.008Bhatla N., Singhal S. Primary HPV screening for cervical cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2020;65:98–108. DOI: 10.1016/j.bpobgyn.2020.02.008Kyrgiou M., Arbyn M., Bergeron C., Bosch F.X., Dillner J., Jit M. et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br. J. Cancer. 2020;123(4):510–517. DOI: 10.1038/s41416-020-0920-9Kyrgiou M., Arbyn M., Bergeron C., Bosch F.X., Dillner J., Jit M. et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br. J. Cancer. 2020;123(4):510–517. DOI: 10.1038/s41416-020-0920-9Verdoodt F., Jentschke M., Hillemanns P., Racey C.S., Snijders P.J.F., Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur. J. Cancer. 2015;51:2375–2385. DOI: 10.1016/j.ejca.2015.07.006Verdoodt F., Jentschke M., Hillemanns P., Racey C.S., Snijders P.J.F., Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur. J. Cancer. 2015;51:2375–2385. DOI: 10.1016/j.ejca.2015.07.006Arbyn M., Gultekin M., Morice P., Nieminen P., Cruickshank M., Poortmans P. et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int. J. Cancer. 2021;148(2):277–284. DOI: 10.1002/ijc.33189Arbyn M., Gultekin M., Morice P., Nieminen P., Cruickshank M., Poortmans P. et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int. J. Cancer. 2021;148(2):277–284. DOI: 10.1002/ijc.33189Pouliakis A., Valasoulis G., Michail G., Salamalekis E., Margari N., Kottaridi C. et al. New Aspects and an artificial intelligence approach for the detection of cervical abnormalities: The COVID-19 Pandemic Era. In: Anastasius M., editor. Quality of Healthcare in the Aftermath of the COVID-19 Pandemic. IGI Global; Hershey, PA, USA: 2022:192–214. DOI: 10.4018/978-1-7998-9198-7.ch011Pouliakis A., Valasoulis G., Michail G., Salamalekis E., Margari N., Kottaridi C. et al. New Aspects and an artificial intelligence approach for the detection of cervical abnormalities: The COVID-19 Pandemic Era. In: Anastasius M., editor. Quality of Healthcare in the Aftermath of the COVID-19 Pandemic. IGI Global; Hershey, PA, USA: 2022:192–214. DOI: 10.4018/978-1-7998-9198-7.ch011Elfström K.M., Dillner J. Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic. medRxiv. 2022;2022:22277806. DOI: 10.1101/2022.07.19.22277806Elfström K.M., Dillner J. Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic. medRxiv. 2022;2022:22277806. DOI: 10.1101/2022.07.19.22277806European Commission European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed.: Supplements. 2022. [Electronic resource]. URL: https://op.europa.eu/pl/publication-detail/-/publication/a41a4c40-0626-4556-af5b-2619dd1d5ddcEuropean Commission European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed.: Supplements. 2022. [Electronic resource]. URL: https://op.europa.eu/pl/publication-detail/-/publication/a41a4c40-0626-4556-af5b-2619dd1d5ddcWoo Y.L., Khoo S.P., Gravitt P., Hawkes D., Rajasuriar R., Saville M. The Implementation of a primary HPV self-testing cervical screening program in malaysia through program ROSE-lessons learnt and moving forward. Curr. Oncol. 2022;29:7379–7387. DOI: 10.3390/curroncol29100579Woo Y.L., Khoo S.P., Gravitt P., Hawkes D., Rajasuriar R., Saville M. The Implementation of a primary HPV self-testing cervical screening program in malaysia through program ROSE-lessons learnt and moving forward. Curr. Oncol. 2022;29:7379–7387. DOI: 10.3390/curroncol29100579World Health Organization. Regional Committee for Europe. Roadmap to accelerate the elimination of cervical cancer as a public health problem in the WHO European Region 2022–2030. Draft for the Seventy-second Regional Committee for Europe Background document. 2022. [Electronic resource]. URL: https://iris.who.int/bitstream/handle/10665/362396/72bg17e-Roadmap-CervicalCancer.pdf?sequence=1&isAllowed=yWorld Health Organization. Regional Committee for Europe. Roadmap to accelerate the elimination of cervical cancer as a public health problem in the WHO European Region 2022–2030. Draft for the Seventy-second Regional Committee for Europe Background document. 2022. [Electronic resource]. URL: https://iris.who.int/bitstream/handle/10665/362396/72bg17e-Roadmap-CervicalCancer.pdf?sequence=1&isAllowed=yAuvinen E., Nieminen P., Pellinen J., Dillner J., Tarkkanen J., Virtanen A. Human papillomavirus self-sampling with mRNA testing benefits routine screening. Int. J. Cancer. 2022;151(11):1989–1996. DOI: 10.1002/ijc.34170Auvinen E., Nieminen P., Pellinen J., Dillner J., Tarkkanen J., Virtanen A. Human papillomavirus self-sampling with mRNA testing benefits routine screening. Int. J. Cancer. 2022;151(11):1989–1996. DOI: 10.1002/ijc.34170Yeh P.T., Kennedy C.E., De Vuyst H., Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob. Health. 2019;4:e001351. DOI: 10.1136/bmjgh-2018-001351Yeh P.T., Kennedy C.E., De Vuyst H., Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob. Health. 2019;4:e001351. DOI: 10.1136/bmjgh-2018-001351Harding-Esch E.M., Hollis E., Mohammed H., Saunders J.M. Self-sampling and self-testing for STIs and HIV: the case for consistent nomenclature. Sex Transm. Infect. 2017;93(2):445–448. DOI: 10.1136/sextrans-2016-052841Harding-Esch E.M., Hollis E., Mohammed H., Saunders J.M. Self-sampling and self-testing for STIs and HIV: the case for consistent nomenclature. Sex Transm. Infect. 2017;93(2):445–448. DOI: 10.1136/sextrans-2016-052841Fargnoli V., Petignat P., Burton-Jeangros C. To what extent will women accept HPV self-sampling for cervical cancer screening? A qualitative study conducted in Switzerland. Int. J. Womens Health. 2015;7:883–8. DOI: 10.2147/IJWH.S90772Fargnoli V., Petignat P., Burton-Jeangros C. To what extent will women accept HPV self-sampling for cervical cancer screening? A qualitative study conducted in Switzerland. Int. J. Womens Health. 2015;7:883–8. DOI: 10.2147/IJWH.S90772Arbyn M., Smith S.B., Temin S., Sultana F., Castle P. Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analysis. BMJ. 2018;363:k4823. DOI: 10.1136/bmj.k4823Arbyn M., Smith S.B., Temin S., Sultana F., Castle P. Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analysis. BMJ. 2018;363:k4823. DOI: 10.1136/bmj.k4823Hawkes D., Keung M.H.T,. Huang Y., McDermott T.L., Romano J., Saville M., Brotherton J.M.L. Self-collection for cervical screening programs: from research to reality. Cancers (Basel). 2020;12(4):1053. DOI: 10.3390/cancers12041053Hawkes D., Keung M.H.T,. Huang Y., McDermott T.L., Romano J., Saville M., Brotherton J.M.L. Self-collection for cervical screening programs: from research to reality. Cancers (Basel). 2020;12(4):1053. DOI: 10.3390/cancers12041053Arbyn M., Verdoodt F., Snijders P.J., Verhoef V.M., Suonio E., Dillner L. et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172–83. DOI: 10.1016/S1470-2045(13)70570-9Arbyn M., Verdoodt F., Snijders P.J., Verhoef V.M., Suonio E., Dillner L. et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172–83. DOI: 10.1016/S1470-2045(13)70570-9Reiter P., Richardson M. Acceptability of human papillomavirus selftest devices among women from high-risk populations. J. Womens Health Issues Care. 2016;5(1). DOI: 10.4172/2325-9795.1000216Reiter P., Richardson M. Acceptability of human papillomavirus selftest devices among women from high-risk populations. J. Womens Health Issues Care. 2016;5(1). DOI: 10.4172/2325-9795.1000216Polman N.J., Ebisch R.M.F., Heideman D.A.M., Melchers W.J.G., Bekkers R.L.M., Molijn A.C. et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20(2):229–238. DOI: 10.1016/S1470-2045(18)30763-0Polman N.J., Ebisch R.M.F., Heideman D.A.M., Melchers W.J.G., Bekkers R.L.M., Molijn A.C. et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20(2):229–238. DOI: 10.1016/S1470-2045(18)30763-0Arbyn M., Castle P.E. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev. 2015;24(5):769– 72. DOI: 10.1158/1055-9965.EPI-14-1417Arbyn M., Castle P.E. Offering self-sampling kits for HPV testing to reach women who do not attend in the regular cervical cancer screening program. Cancer Epidemiol Biomarkers Prev. 2015;24(5):769– 72. DOI: 10.1158/1055-9965.EPI-14-1417Madzima T.R., Vahabi M., Lofters A. Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: Focused literature review. Can Fam Physician. 2017;63(8):597–601. [Electronic resource]. URL: https://pubmed.ncbi.nlm.nih.gov/28807952/Madzima T.R., Vahabi M., Lofters A. Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: Focused literature review. Can Fam Physician. 2017;63(8):597–601. [Electronic resource]. URL: https://pubmed.ncbi.nlm.nih.gov/28807952/Lozar T., Nagvekar R., Rohrer C., Dube Mandishora R.S., Ivanus U., Fitzpatrick M.B.. Cervical cancer screening postpandemic: self-sampling opportunities to accelerate the elimination of cervical cancer. Int. J. Womens Health. 2021;13:841–859. DOI: 10.2147/IJWH.S288376Lozar T., Nagvekar R., Rohrer C., Dube Mandishora R.S., Ivanus U., Fitzpatrick M.B.. Cervical cancer screening postpandemic: self-sampling opportunities to accelerate the elimination of cervical cancer. Int. J. Womens Health. 2021;13:841–859. DOI: 10.2147/IJWH.S288376Bosgraaf R.P., Verhoef V.M., Massuger L.F., Siebers A.G., Bulten J., de Kuyper-de Ridder G.M. et al. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int. J. Cancer. 2015;136(3):646–55. DOI: 10.1002/ijc.29026Bosgraaf R.P., Verhoef V.M., Massuger L.F., Siebers A.G., Bulten J., de Kuyper-de Ridder G.M. et al. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int. J. Cancer. 2015;136(3):646–55. DOI: 10.1002/ijc.29026Di Gennaro G., Licata F., Trovato A., Bianco A. Does self-sampling for human papilloma virus testing have the potential to increase cervical cancer screening? An updated meta-analysis of observational studies and randomized clinical trials. Front. Public Health. 2022;10:1003461. DOI: 10.3389/fpubh.2022.1003461Di Gennaro G., Licata F., Trovato A., Bianco A. Does self-sampling for human papilloma virus testing have the potential to increase cervical cancer screening? An updated meta-analysis of observational studies and randomized clinical trials. Front. Public Health. 2022;10:1003461. DOI: 10.3389/fpubh.2022.1003461Van Keer S., Peeters E., Vanden Broeck D., De Sutter P., Donders G., Doyen J. et al. Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. Gynecol. Oncol. 2021;162(3):575–583. DOI: 10.1016/j.ygyno.2021.06.010Van Keer S., Peeters E., Vanden Broeck D., De Sutter P., Donders G., Doyen J. et al. Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. Gynecol. Oncol. 2021;162(3):575–583. DOI: 10.1016/j.ygyno.2021.06.010Lefeuvre C., Pivert A., Guillou-Guillemette H.L., Lunel-Fabiani F., Veillon P., Le Duc-Banaszuk A.S., Ducancelle A. Urinary HPV DNA testing as a tool for cervical cancer screening in women who are reluctant to have a Pap smear in France. J. Infect. 2020;81(2):248–254. DOI: 10.1016/j.jinf.2020.05.006Lefeuvre C., Pivert A., Guillou-Guillemette H.L., Lunel-Fabiani F., Veillon P., Le Duc-Banaszuk A.S., Ducancelle A. Urinary HPV DNA testing as a tool for cervical cancer screening in women who are reluctant to have a Pap smear in France. J. Infect. 2020;81(2):248–254. DOI: 10.1016/j.jinf.2020.05.006Colli-Pee: An innovative solution for non-invasive urine collection and stabilization. Novosanis. 2021. [Electronic resource]. URL: https://novosanis.com/our-productsColli-Pee: An innovative solution for non-invasive urine collection and stabilization. Novosanis. 2021. [Electronic resource]. URL: https://novosanis.com/our-productsLi J., Wu R., Qu X., Huang X., Li L., Lin Z. et al. Effectiveness and feasibility of self-sampling for human papillomavirus testing for internet-based cervical cancer screening. Front Public Health. 2022;10:938272. DOI: 10.3389/fpubh.2022.938272Li J., Wu R., Qu X., Huang X., Li L., Lin Z. et al. Effectiveness and feasibility of self-sampling for human papillomavirus testing for internet-based cervical cancer screening. Front Public Health. 2022;10:938272. DOI: 10.3389/fpubh.2022.938272Smith M.A., Hall M.T., Saville M., Brotherton J.M.L., Simms K.T., Lew J.B. et al. Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. Cancer Epidemiol Biomarkers Prev. 2021;30(2):268–277. DOI: 10.1158/1055-9965Smith M.A., Hall M.T., Saville M., Brotherton J.M.L., Simms K.T., Lew J.B. et al. Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. Cancer Epidemiol Biomarkers Prev. 2021;30(2):268–277. DOI: 10.1158/1055-9965

The authors declare that there are no conflicts of interest present.